This site uses cookies to improve your experience and to provide services and advertising. By continuing to browse, you agree to the use of cookies described in our Cookies Policy. You may change your settings at any time but this may impact on the functionality of the site. To learn more see our Cookies Policy.
OK
#Open journalism No news is bad news

Your contributions will help us continue to deliver the stories that are important to you

Support The Journal
Dublin: 18 °C Monday 13 July, 2020
Advertisement

US drugmaker reports promising early results from Covid-19 vaccine test

Moderna, which was founded nine years ago, said the vaccine “was generally safe and well-tolerated”.

Image: DPA/PA Images

US FIRM MODERNA reported promising early results today from the first clinical tests of an experimental vaccine against the coronavirus performed on a small number of volunteers.

The Cambridge, Massachusetts-based company said the vaccine candidate, mRNA-1273, appeared to produce an immune response in eight people who received it similar to that seen in people convalescing from the virus.

“These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection,” said Moderna’s chief medical officer Tal Zaks.

“These data substantiate our belief that mRNA-1273 has the potential to prevent Covid-19 disease and advance our ability to select a dose for pivotal trials,” Zaks said.

Wall Street stocks jumped in early trading on the news, with the Dow Jones Industrial Average gaining around 775 points, or 3.3%.

“It’s incredible what they can do and I’ve seen results. And the results are staggeringly good. So I’m very happy and the market’s up very big,” President Donald Trump told reporters.

Moderna, which was founded nine years ago, said the vaccine “was generally safe and well-tolerated” and that patients suffered no more than redness or soreness from the shots.

In a conference call, Moderna chief executive Stephane Bancel said the preliminary tests inspired confidence that mRNA-1273 has “a high probability to provide protection” against the virus.

“We could not be happier about these interim data,” Bancel said of the Phase 1 test, the first of three in the development of a vaccine. 

Separate tests performed on mice showed that the vaccine prevented the virus from replicating in their lungs, according to the company.

The US government has invested nearly half a billion dollars in the development of Moderna’s vaccine candidate.

It is being developed in a partnership with the National Institute of Allergy and Infectious Disease headed by Anthony Fauci and the clinical test was carried out by the National Institutes of Health.

Three groups of 15 patients aged 18 to 55 received three different doses of the vaccine in the Phase 1 test, the complete results of which are not yet known.

The Phase 2 trial, with 600 subjects, has already received the green light from the US Food and Drug Administration and Moderna said they should begin this quarter.

#Open journalism No news is bad news Support The Journal

Your contributions will help us continue to deliver the stories that are important to you

Support us now

A Phase 3 trial, the largest and most important to validate the efficacy of a vaccine, should begin in July.

It will not be until the Phase 3 trial is completed that it will be known whether the vaccine actually prevents Covid-19 disease.

Trump has said he wants 300 million vaccine doses by January 2021 to protect the US population and his administration has provided funding to Moderna, Johnson & Johnson, and France’s Sanofi.

The development of a vaccine usually takes years but the coronavirus pandemic, which has caused more than 315,000 deaths, has given unprecedented urgency to the search.

A dozen clinical trials are taking place around the world, half of them in China, according to the London School of Hygiene & Tropical Medicine.

- © AFP 2020  

  • Share on Facebook
  • Email this article
  •  

About the author:

AFP

Read next:

COMMENTS (37)

This is YOUR comments community. Stay civil, stay constructive, stay on topic. Please familiarise yourself with our comments policy here before taking part.
write a comment

    Leave a commentcancel